JP6368383B2 - 鉱質コルチコイド受容体修飾因子としてのベンゾオキサジノンアミド - Google Patents

鉱質コルチコイド受容体修飾因子としてのベンゾオキサジノンアミド Download PDF

Info

Publication number
JP6368383B2
JP6368383B2 JP2016575499A JP2016575499A JP6368383B2 JP 6368383 B2 JP6368383 B2 JP 6368383B2 JP 2016575499 A JP2016575499 A JP 2016575499A JP 2016575499 A JP2016575499 A JP 2016575499A JP 6368383 B2 JP6368383 B2 JP 6368383B2
Authority
JP
Japan
Prior art keywords
dihydro
benzoxazin
oxo
carbonyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016575499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522300A5 (https=
JP2017522300A (ja
Inventor
ギャビン・オマホニー
ミーケル・コッセンヤンス
カール・エドマン
ヨハン・カヤヌス
カール・アンデシュ・ホグナー
フィリップ・コーンウォール
アンドリュー・ターナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2017522300A publication Critical patent/JP2017522300A/ja
Publication of JP2017522300A5 publication Critical patent/JP2017522300A5/ja
Application granted granted Critical
Publication of JP6368383B2 publication Critical patent/JP6368383B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2016575499A 2014-06-30 2015-06-26 鉱質コルチコイド受容体修飾因子としてのベンゾオキサジノンアミド Active JP6368383B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018790P 2014-06-30 2014-06-30
US62/018,790 2014-06-30
PCT/GB2015/051860 WO2016001631A1 (en) 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators

Publications (3)

Publication Number Publication Date
JP2017522300A JP2017522300A (ja) 2017-08-10
JP2017522300A5 JP2017522300A5 (https=) 2018-07-19
JP6368383B2 true JP6368383B2 (ja) 2018-08-01

Family

ID=53539739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575499A Active JP6368383B2 (ja) 2014-06-30 2015-06-26 鉱質コルチコイド受容体修飾因子としてのベンゾオキサジノンアミド

Country Status (26)

Country Link
US (2) US10017502B2 (https=)
EP (1) EP3160948B1 (https=)
JP (1) JP6368383B2 (https=)
KR (1) KR102012222B1 (https=)
CN (1) CN106536491B (https=)
AR (1) AR101036A1 (https=)
AU (1) AU2015282450C1 (https=)
CA (1) CA2953655C (https=)
CY (1) CY1121596T1 (https=)
DK (1) DK3160948T3 (https=)
EA (1) EA029518B1 (https=)
ES (1) ES2707726T3 (https=)
HR (1) HRP20190147T1 (https=)
HU (1) HUE042370T2 (https=)
LT (1) LT3160948T (https=)
ME (1) ME03316B (https=)
MX (1) MX367404B (https=)
PL (1) PL3160948T3 (https=)
PT (1) PT3160948T (https=)
RS (1) RS58274B1 (https=)
SI (1) SI3160948T1 (https=)
SM (1) SMT201900039T1 (https=)
TR (1) TR201900659T4 (https=)
TW (1) TWI677498B (https=)
UY (1) UY36195A (https=)
WO (1) WO2016001631A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3160948B1 (en) * 2014-06-30 2018-10-24 Astrazeneca AB Benzoxazinone amides as mineralocorticoid receptor modulators
MA53175A (fr) 2018-07-19 2021-05-26 Astrazeneca Ab Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
PE20211267A1 (es) 2019-08-30 2021-07-19 Astrazeneca Ab Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina
CN116392472B (zh) 2020-07-27 2025-06-20 阿斯利康(瑞典)有限公司 用达格列净治疗慢性肾脏病的方法
US12409186B2 (en) 2020-07-27 2025-09-09 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
MX2023015144A (es) 2021-06-15 2024-01-22 Chia Tai Tianqing Pharmaceutical Group Co Ltd Derivados de benzoxazinona.
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
AU2023331475A1 (en) 2022-09-01 2025-04-17 Astrazeneca Ab Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases
WO2024125591A1 (zh) * 2022-12-15 2024-06-20 正大天晴药业集团股份有限公司 苯并恶嗪酮类化合物的结晶及其制备
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951855B2 (en) * 2001-04-23 2005-10-04 Astrazeneca Ab Benzoxazinone derivatives for use in the treatment of angiogenesis
CA2510851A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
CN101018552A (zh) * 2004-07-14 2007-08-15 利亘制药公司 细胞内受体调节剂化合物和方法
US20090054417A1 (en) * 2004-07-28 2009-02-26 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
CA2635541A1 (en) 2005-12-28 2007-07-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
DK2089367T3 (da) 2006-10-31 2012-02-06 Pfizer Prod Inc Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
EP2139489A4 (en) 2007-03-23 2011-11-02 Merck Sharp & Dohme Mineralocorticoid receptor modulators
EP2133330B1 (en) 2007-04-09 2014-01-01 Daiichi Sankyo Company, Limited Atropisomer of pyrrole derivative
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
UY31905A (es) * 2008-06-18 2010-01-29 Astrazeneca Ab Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2010098286A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
WO2010104721A1 (en) 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
JP2012523405A (ja) 2009-04-10 2012-10-04 ファイザー・インク ４，５−ジヒドロ−１ｈ−ピラゾール化合物およびその薬学的使用
WO2011141848A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
WO2011141846A2 (en) 2010-05-11 2011-11-17 Koninklijke Philips Electronics N.V. Lighting module
US20130116227A1 (en) 2010-07-13 2013-05-09 Dainippon Sumitomo Pharma Co., Ltd. Biaryl amide derivative or pharmaceutically acceptable salt thereof
JP2013542255A (ja) 2010-11-10 2013-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ミネラルコルチコイド受容体アンタゴニストとしてのピリジル尿素
EP3160948B1 (en) * 2014-06-30 2018-10-24 Astrazeneca AB Benzoxazinone amides as mineralocorticoid receptor modulators

Also Published As

Publication number Publication date
AR101036A1 (es) 2016-11-16
KR102012222B1 (ko) 2019-10-21
EP3160948B1 (en) 2018-10-24
ES2707726T3 (es) 2019-04-04
AU2015282450A1 (en) 2017-02-02
JP2017522300A (ja) 2017-08-10
TW201613909A (en) 2016-04-16
EP3160948A1 (en) 2017-05-03
AU2015282450B2 (en) 2018-05-10
HRP20190147T1 (hr) 2019-03-22
US20150376170A1 (en) 2015-12-31
EA029518B1 (ru) 2018-04-30
HUE042370T2 (hu) 2019-06-28
ME03316B (me) 2019-10-20
WO2016001631A1 (en) 2016-01-07
TWI677498B (zh) 2019-11-21
LT3160948T (lt) 2019-02-11
US20170217945A1 (en) 2017-08-03
DK3160948T3 (en) 2019-02-18
TR201900659T4 (tr) 2019-02-21
CN106536491B (zh) 2018-12-18
PL3160948T3 (pl) 2019-04-30
SMT201900039T1 (it) 2019-02-28
EA201790046A1 (ru) 2017-08-31
CN106536491A (zh) 2017-03-22
CY1121596T1 (el) 2020-05-29
US10017502B2 (en) 2018-07-10
MX2017000183A (es) 2017-04-25
CA2953655A1 (en) 2016-01-07
MX367404B (es) 2019-08-20
PT3160948T (pt) 2019-02-01
UY36195A (es) 2016-01-08
SI3160948T1 (sl) 2020-06-30
RS58274B1 (sr) 2019-03-29
US9394291B2 (en) 2016-07-19
CA2953655C (en) 2020-05-12
KR20170021883A (ko) 2017-02-28
AU2015282450C1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
JP6368383B2 (ja) 鉱質コルチコイド受容体修飾因子としてのベンゾオキサジノンアミド
JP5564036B2 (ja) ヒストン脱アセチル化酵素阻害薬としてのスピロ環誘導体
JP6466433B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
KR101738866B1 (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도
SK361392A3 (en) Azaheterocyclylmethyl-chromans, method for producing them, their use and pharmaceutical composition containing same
JP2015514073A (ja) スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンｂａｃｅ阻害剤、ならびにその組成物および使用
EA024933B1 (ru) Фенил-3-азабицикло[3.1.0]гекс-3-илметаноны и их применение в качестве лекарственного средства
KR102720397B1 (ko) 질환 치료용 복소환식 화합물
TW202222770A (zh) 苄胺或苄醇衍生物及其用途
CN105073724A (zh) 作为钾离子通道抑制剂的2,3-二氮杂萘类化合物
WO2023166303A1 (en) Acrylamide compounds
CA2841897A1 (en) Novel compound having parp inhibitory activity
HUT54151A (en) Process fopr producing new (r)-(-)-3-quinuclidinone derivatives and pharmaceutical compositions comprising such compounds
CZ281714B6 (cs) Piperidylmethylsubstituované deriváty chromanu
HK1237338A1 (en) Benzoxazinone amides as mineralocorticoid receptor modulators
HK1237338B (en) Benzoxazinone amides as mineralocorticoid receptor modulators
EP3204385A1 (en) Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
KR19990028550A (ko) 편두통 치료용의 1,6-이치환된 이소크로만

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180306

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180306

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180607

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180614

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180619

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180706

R150 Certificate of patent or registration of utility model

Ref document number: 6368383

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250